By Chase Doyle
San Francisco—An investigational agent designed to improve conventional opioid pharmacology has demonstrated efficacy and safety, as well as faster onset of action, in a pair of pivotal trials.
Compared with placebo, patients receiving IV oliceridine (Olinvo, Trevena), a G protein-biased ligand (GPBL) at the mu-opioid receptor, experienced superior relief following bunionectomy or abdominoplasty. Oliceridine also showed favorable trends in respiratory safety and upper